Blockade of EC-mediated anti-VCAM1 interactions via biologics, including natalizumab and vedolizumab, has proven effective in ameliorating T-cell homing to inflamed tissues in autoimmune disease and may show promise in blocking immune complications attendant to VCAs. This evidence concerns the gene VCAM1 and autoimmune disease.